137 related articles for article (PubMed ID: 11957800)
21. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
Andius P; Holmäng S
BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
[TBL] [Abstract][Full Text] [Related]
22. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
23. Intravesical epirubicin treatment following TUR in superficial bladder tumours.
Imamoğlu MA; Bakirtaş H; Yiğitbaşi O; Ersoy H; Sertçelik AN
Arch Esp Urol; 2001 Dec; 54(10):1147-53. PubMed ID: 11852530
[TBL] [Abstract][Full Text] [Related]
24. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association].
Descazeaud A; Mignard JP; Davin JL; Irani J
Prog Urol; 2009 Oct; 19(9):624-31. PubMed ID: 19800553
[TBL] [Abstract][Full Text] [Related]
26. [BCG infection of the glans penis after intravesical BCG therapy].
Michelet N; Spenatto N; Viraben R; Cuny JF; Mazet J; Trechot P; Barbaud A; Schmutz JL
Ann Dermatol Venereol; 2008; 135(6-7):479-83. PubMed ID: 18598797
[TBL] [Abstract][Full Text] [Related]
27. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
[TBL] [Abstract][Full Text] [Related]
28. Pure squamous cell carcinoma after intravesical BCG treatment. A case report.
Yurdakul T; Avunduk MC; Piskin MM
Urol Int; 2005; 74(3):283-5. PubMed ID: 15812221
[TBL] [Abstract][Full Text] [Related]
29. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
[TBL] [Abstract][Full Text] [Related]
30. [Results of clinical study with epirubicin hydrochloride injectable solution for superficial bladder cancer. IMI28 Injectable Solution Study Group for Superficial Bladder Cancer].
Kotake T; Koyanagi T; Akaza H; Shimazaki J; Ito H; Hosaka M; Okajima E; Saito Y; Miyanaga N; Kuroda M; Hirao Y
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1189-95. PubMed ID: 9679582
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.
Agrawal MS; Agrawal M; Bansal S; Agarwal M; Lavania P; Goyal J
Urology; 2007 Dec; 70(6):1075-8. PubMed ID: 18158020
[TBL] [Abstract][Full Text] [Related]
32. [Intravesical chemotherapy with 4'-Epi-Adriamycin in patients with superficial bladder tumors].
Tsushima T; Matsumura Y; Ozaki Y; Yoshimoto J; Obama T; Akagi T; Nasu Y; Ohmori H
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2502-5. PubMed ID: 6594972
[TBL] [Abstract][Full Text] [Related]
33. [Systemic BCG reactions after intravesical BCG therapy. A report of four cases].
Sfaxi M; Langar H; Ouni A; Riahi Y; El Aidli S; Daghfous R; Ben Abdeladhim A; Chébil M
Therapie; 2008; 63(1):43-7. PubMed ID: 18387275
[TBL] [Abstract][Full Text] [Related]
34. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?
Damiano R; De Sio M; Quarto G; Di Lorenzo G; Perdonà S; Palumbo IM; Azzarito G; Giugliano F; Autorino R
BJU Int; 2009 Sep; 104(5):633-9. PubMed ID: 19298412
[TBL] [Abstract][Full Text] [Related]
35. Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906).
Mehraban D; Esfahani F
J Urol; 2005 Sep; 174(3):1151; author reply 1151. PubMed ID: 16094088
[No Abstract] [Full Text] [Related]
36. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
Hameed A; Sezian N; Thwaini A
Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
[TBL] [Abstract][Full Text] [Related]
37. [Complications of endovesical treatment with BCG in a series of 200 patients].
Resel Folkersma LE; Belón Lopéz Tomasetti JA; Isorna Martínez de la Riva S; Caminero Luna JA
Arch Esp Urol; 1999 Nov; 52(9):957-65. PubMed ID: 10633963
[TBL] [Abstract][Full Text] [Related]
38. Clinical study of bladder cancer: Proteinuria as a predictor of recurrence and efficacy of intravesical bacille Calmette-Guerin therapy.
Satoh A; Hanawa Y; Nakamura S
Int J Urol; 2004 Jul; 11(7):476-82. PubMed ID: 15242355
[TBL] [Abstract][Full Text] [Related]
39. [Calmette-Guerin bacillus disseminated infection after intravesical instillation].
Borré S; Brustia D; Rosa F; Brondolo R; Rizzo G; Garavelli PL
Recenti Prog Med; 2002 Apr; 93(4):247-8. PubMed ID: 11989131
[TBL] [Abstract][Full Text] [Related]
40. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes.
Liu B; Wang Z; Chen B; Yu J; Zhang P; Ding Q; Zhang Y
Cancer Invest; 2006 Mar; 24(2):160-3. PubMed ID: 16537185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
